Krystal Biotech (KRYS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Krystal Biotech

NasdaqGS•Healthcare•Biotechnology

$311.10+6.07(0.02%)Market open

Market Cap

$9.01B

P/E

37.3x

P/S

20.4x

P/B

6.6x

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

How this company scores

ExcellentMetricSide Score: 88/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 37.3x5y range 25.7x – 440.8x

Currently near its 11-quarter median.

P/S · 20.4x5y range 11.1x – 560.0x

Currently near its 12-quarter median.

P/B · 6.6x5y range 3.8x – 9.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Share Dilution

Watch

Shares outstanding rose 2.8% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $9.01B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $440.48M
Q. Revenue: $119.22M
TTM EBITDA: $203.76M
TTM Op. Income: $197.92M
Q. Op. Income: $58.42M
TTM Net Income: $241.47M
Q. Net Income: $54.77M
EPS: $1.85
Shares Out.: $29.53M

$440.48M in TTM revenue grew 22.6% YoY, reaching $119.22M last quarter. TTM EBITDA of $203.76M and TTM operating income of $197.92M show growth is flowing through to the bottom line. TTM net income of $241.47M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 94.6%
EBITDA Margin: 50.1%
Op. Margin: 49.0%
Net Margin: 45.9%

Op. margin of 49.0% is up 8.1% YoY — cost efficiency is improving. Net margin at 45.9% and gross margin of 94.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 37.3x
P/S Ratio: 20.4x
P/B Ratio: 6.6x

At 37.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 20.4x and P/B of 6.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 38% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.50B
Cash: $427.74M
Long-Term Debt: N/A
Book Value: $1.36B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $74.79M
TTM Free Cash Flow: $257.78M
FCF Margin: 58.5%
FCF / Net Income: 1.1

TTM FCF of $257.78M on $74.79M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.